君实生物-B(01877.HK)控股股东熊俊受让共青城君拓持有的公司股份
格隆汇7月29日丨君实生物-B(01877.HK)发布公告,2019年7月25日,公司控股股东、实际控制人之一熊俊通过盘后协议转让方式受让共青城君拓投资管理有限合伙企业持有的全部公司股份,使得挂牌公司控股股东、实际控制人之一的一致行动人发生变更,变更为熊俊、熊凤祥、苏州瑞源盛本生物医药管理合伙企业、苏州本裕天源生物科技合伙企业等。
此外,2019年7月26日,熊俊与周玉清签署了一致行动协议,协议签署完成后,公司实际控制人熊俊、熊凤祥实际控制的股份表决权比例为27.7029%。该协议的签署利于巩固控股股东的控制地位,稳定公司现有治理结构。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.